Results 201 to 210 of about 29,229,093 (355)

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

A buffer-tuning strategy to profile domain-specific activity of chimeric I-TevI/CRISPR gene editors in vitro. [PDF]

Sci Rep
Loedige KW, White AL, McMurrough TA, Stead BE, Edgell DR.   +4 more
europepmc   +1 more source

Improvement of optimum pH and specific activity of pectate lyase from Bacillus RN.1 using loop replacement. [PDF]

Front Bioeng Biotechnol, 2023
Li P, Wei X, Wang Y, Liu H, Xu Y, Zhang Z, Li J, Wang J, Guo C, Sui S, Wang J, Wang R.   +11 more
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Integrated In Vitro and In Silico Profiling of Piperazinyl Thiosemicarbazone Derivatives Against Trypanosoma cruzi: Stage-Specific Activity and Enzyme Inhibition. [PDF]

Pharmaceuticals (Basel)
Baldoni HA, Sbaraglini ML, Balcazar DE, Arias DG, Guerrero SA, Alba Soto CD, Cieslik W, Rogalska M, Polański J, Enriz RD, Jampilek J, Musiol R.   +11 more
europepmc   +1 more source

Studies of the Specific Activity of Aerosolized Isoniazid against Tuberculosis in a Mouse Model. [PDF]

Antibiotics (Basel), 2022
Valiulin SV, Onischuk AA, Baklanov AM, Dubtsov SN, Dultseva GG, An'kov SV, Tolstikova TG, Belogorodtsev SN, Schwartz YS.   +8 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

A Novel Cobalt-Activated Halotolerant α-Amylase with High Specific Activity from <i>Priestia</i> sp. W243 in Kuwait Sabkha for Biotechnological Applications. [PDF]

Mar Drugs
Alagarsamy S, Habeebullah SFK, Azad IS, Fakhraldeen SA, Al Said T, Al Ghuniam A, Al-Yamani F.   +6 more
europepmc   +1 more source

Antibacterial effectors in Dictyostelium discoideum: specific activity against different bacterial species. [PDF]

mSphere
Munoz-Ruiz R, Lamrabet O, Jauslin T, Guilhen C, Bourbon A, Cosson P.   +5 more
europepmc   +2 more sources

Novel specific activity-based probes validate KLK proteases as druggable targets. [PDF]

Cancer Biol Ther, 2022
Sotiropoulou G, Zingkou E, Pampalakis G.
europepmc   +1 more source